Synlogic Management

Management criteria checks 3/4

Synlogic's CEO is Aoife Brennan, appointed in May 2018, has a tenure of 5.58 years. total yearly compensation is $1.68M, comprised of 35.3% salary and 64.7% bonuses, including company stock and options. directly owns 0.19% of the company’s shares, worth €56.49K. The average tenure of the management team and the board of directors is 2.9 years and 6.3 years respectively.

Key information

Aoife Brennan

Chief executive officer

US$1.7m

Total compensation

CEO salary percentage	35.3%
CEO tenure	5.6yrs
CEO ownership	0.2%
Management average tenure	2.9yrs
Board average tenure	6.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Aoife Brennan's remuneration changed compared to Synlogic's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2023	n/a	n/a	-US$59m
Jun 30 2023	n/a	n/a	-US$65m
Mar 31 2023	n/a	n/a	-US$66m
Dec 31 2022	US$2m	US$595k	-US$66m
Sep 30 2022	n/a	n/a	-US$65m
Jun 30 2022	n/a	n/a	-US$63m
Mar 31 2022	n/a	n/a	-US$61m
Dec 31 2021	US$2m	US$570k	-US$61m
Sep 30 2021	n/a	n/a	-US$60m
Jun 30 2021	n/a	n/a	-US$57m
Mar 31 2021	n/a	n/a	-US$58m
Dec 31 2020	US$1m	US$550k	-US$59m
Sep 30 2020	n/a	n/a	-US$57m
Jun 30 2020	n/a	n/a	-US$57m
Mar 31 2020	n/a	n/a	-US$54m
Dec 31 2019	US$2m	US$505k	-US$51m
Sep 30 2019	n/a	n/a	-US$51m
Jun 30 2019	n/a	n/a	-US$48m
Mar 31 2019	n/a	n/a	-US$50m
Dec 31 2018	US$2m	US$451k	-US$48m
Sep 30 2018	n/a	n/a	-US$48m
Jun 30 2018	n/a	n/a	-US$49m
Mar 31 2018	n/a	n/a	-US$44m
Dec 31 2017	US$1m	US$349k	-US$40m
Sep 30 2017	n/a	n/a	-US$36m
Jun 30 2017	n/a	n/a	-US$29m
Mar 31 2017	n/a	n/a	-US$24m
Dec 31 2016	US$386k	US$115k	-US$21m

Compensation vs Market: Aoife's total compensation ($USD1.68M) is above average for companies of similar size in the German market ($USD427.28K).

Compensation vs Earnings: Aoife's compensation has been consistent with company performance over the past year.

CEO

Aoife Brennan (47 yo)

5.6yrs

Tenure

US$1,684,450

Compensation

Dr. Aoife M. Brennan, M.D. M.B., Ch B., BAO, MMSc, MRCPI, serves as Director at FibroGen, Inc. since August 5, 2020. Dr. Brennan serves as Director at Cerevance LLC.from January 1, 2020. She served as Dir...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Aoife Brennan	President	5.6yrs	US$1.68m	0.19% $ 56.5k
Antoine Awad	Chief Operating Officer	3.4yrs	US$876.33k	0.054% $ 16.5k
Timothy Lu	Co-Founder & Member of Scientific Advisory Board	no data	no data	no data
James Collins	Co-Founder & Member of Scientific Advisory Board	no data	no data	no data
Mary Dooley	VP & Head of Finance	less than a year	no data	no data
Brendan Amant	General Counsel & Corporate Secretary	2.9yrs	no data	no data
Ajay Munshi	Vice President of Corporate Development	no data	no data	no data
Adam Thomas	Chief People Officer	6.2yrs	no data	no data
Caroline Kurtz	Chief Development Officer	7.3yrs	no data	no data
Molly Harper	Chief Business Officer	2.3yrs	no data	no data
Neal Sondheimer	VP & Head of Clinical	less than a year	no data	no data
Mylene Perreault	VP & Head of Research	less than a year	no data	no data

2.9yrs

Average Tenure

46yo

Average Age

Experienced Management: MIN's management team is considered experienced (2.9 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Aoife Brennan	President	5.2yrs	US$1.68m	0.19% $ 56.5k
Timothy Lu	Co-Founder & Member of Scientific Advisory Board	no data	no data	no data
James Collins	Co-Founder & Member of Scientific Advisory Board	no data	no data	no data
Richard Shea	Independent Director	6.3yrs	US$77.02k	0.0054% $ 1.7k
Peter Barrett	Independent Chairman of the Board	9.4yrs	US$103.52k	0% $ 0
Edward Mathers	Independent Director	11.2yrs	US$67.02k	0% $ 0
Michael Heffernan	Independent Director	3yrs	US$77.52k	0% $ 0
Nick Leschly	Independent Director	7.8yrs	US$67.02k	0.017% $ 5.1k
Lisa Kelly-Croswell	Independent Director	2.8yrs	US$77.20k	0% $ 0
Paul Miller	Member Scientific Advisory Board	no data	US$956.81k	no data
Charlotte Hubbert	Observer	no data	no data	no data
Cammie Lesser	Member of Scientific Advisory Board	no data	no data	no data

6.3yrs

Average Tenure

58yo

Average Age

Experienced Board: MIN's board of directors are considered experienced (6.3 years average tenure).

Synlogic Management

Management criteria checks 3/4

Key information

Recent management updates

Synlogic, Inc. Announces Departure of Aoife Brennan as President

Synlogic, Inc. Appoints Chief Financial Officer Changes, Effective December 1, 2023

Synlogic, Inc. Appoints Dave Hava as Head of Research and Development

Synlogic, Inc. Announces Appointment of Brendan St. Amant as Corporate Secretary, Effective July 1, 2022

Synlogic Announces Appointment of Michael Jensen as Chief Financial Officer

Synlogic, Inc Announces Promotion of Dr. Caroline Kurtz to Chief Development Officer

Recent updates

Cable Car Capital Discloses its Views on Synlogic

Synlogic, Inc. Announces Departure of Aoife Brennan as President

Synlogic, Inc. Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria

Synlogic, Inc. Appoints Chief Financial Officer Changes, Effective December 1, 2023

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

Synlogic, Inc. Announces Implementation of Reduction in Workforce

Synlogic, Inc. Announces Initiation of Synpheny-3 Global, Pivotal Phase 3 Study Evaluating SYNB1934 for Treatment of Phenylketonuria

Synlogic, Inc. Receives Rare Pediatric Disease Designation from FDA for SYNB1934 for Phenylketonuria

Synlogic, Inc. Appoints Dave Hava as Head of Research and Development

Synlogic Receives Non-Compliance Notice From Nasdaq

Synlogic Announces SYNB1353 Achieves Proof of Mechanism for Treatment of Homocystinuria and Provides Business Update

Synlogic Announces Positive Top-Line Phase 2 Data for Phenylketonuria (PKU) SYNB1934 Advances to Phase 3

Synlogic, Inc Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks

Synlogic, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Synlogic, Inc. Initiates Phase 1 Study of SYNB1353 for the Treatment of Homocystinuria

Synlogic, Inc. Announces Appointment of Brendan St. Amant as Corporate Secretary, Effective July 1, 2022

Synlogic, Inc. to Report Q1, 2022 Results on May 12, 2022

Synlogic to Present Data on Phenylketonuria and Homocystinuria Programs At the Society for Inherited Metabolic Disorders 43Rd Annual Meeting

Synlogic Announces Appointment of Michael Jensen as Chief Financial Officer

Synlogic Presents Data on SYNB8802 for Enteric Hyperoxaluria at American Urological Association (AUA) Annual Meeting

Chief Medical Officer Richard Riese has left the company

Synlogic Announces Initiation of Phase 1 Study of SYNB1934 for treatment of Phenylketonuria

Synlogic, Inc. Presents Additional Preclinical Data on Therapeutic Candidates SYNB1934 for Phenylketonuria (PKU) and SYNB8802 for Enteric Hyperoxaluria at Synthetic Biology: Engineering, Evolution & Design (SEED) Conference

Independent Director Chau Khuong has left the company

Synlogic, Inc. Provides Update on its Clinical and Preclinical Programs

Full year 2020 earnings released: US$1.65 loss per share (vs US$1.70 loss in FY 2019)

Synlogic, Inc. to Report Q4, 2020 Results on Mar 25, 2021

Synlogic, Inc Announces Promotion of Dr. Caroline Kurtz to Chief Development Officer

Synlogic Appoints Lisa Kelly-Croswell to Its Board of Directors

New 90-day high: €3.56

New 90-day high: €2.96

Synlogic, Inc. Announces Advancement of SYNB1891

Synlogic, Inc. Appoints Michael Heffernan to its Board of Directors

New 90-day high: €2.60

Revenue misses expectations

Synlogic, Inc. Initiates Phase 1 Study of SYNB8802 for the Treatment of Enteric Hyperoxaluria

Synlogic, Inc. to Report Q3, 2020 Results on Nov 05, 2020

New 90-day low: €1.60

Synlogic, Inc.(NasdaqGM:SYBX) dropped from S&P Global BMI Index

Synlogic, Inc.(NasdaqGM:SYBX) dropped from Russell Small Cap Completeness Index

Synlogic, Inc.(NasdaqGM:SYBX) dropped from Russell 2000 Dynamic Index

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age